Skip to main content
. 2021 Aug 12;13(8):1244. doi: 10.3390/pharmaceutics13081244

Table 1.

Summary of specifications of selected models.

Model No. Study No. of Patients (Total No. of Samples) Parameter Values and Covariate Relationships Included IIV (CV) Residual Variability
M1 FDA, 2008 646 adult patients (NA) CL/F (L/h)=0.0127
V/F (L)=9.39+0.126· (WT72))
ka (1/h)=0.027 FIX
IIV-CL/F: 16.4%
IIV-V/F: 35.1%
Prop = 31.6%
M2 Ternant D et al., 2015 65 adult CD patients (341) CL/F (L/h)=0.0175· (1+4.5 ·AAA)
V/F (L)=13.5
ka (1/h)=0.00625
IIV-CL/F: 65%
IIV-V/F: 48%
Add = 1.8 mg/L
Prop = 16%
M3 Sharma S et al., 2015 189 pediatric CD patients (852) CL/F (L/h)=0.0117· (1+1.08·AAA)· (WT/45.2)0.48
V/F (L)=4.75 · (WT/45.2)0.904
ka (1/h)=0.00833
IIV-CL/F: 21.1% Add = 1.9 mg/L
Prop = 7.1%
M4 Berends SE et al., 2018 96 adult CD patients (181) CL/F (L/h)=0.0133·(1+3.14·AAA)·(1+0.4·DOSING)
V/F (L)=4.07
ka (1/h)=0.00833 FIX
IIV-CL/F: 49.1% Add = 1.02 mg/L
Prop = 9%
M5 Vande Castelee et al., 2019 28 adult CD patients (185) CL/F (L/h)=0.01375· (1+1.59· AAA)· (LBW/47.8)1.97
V/F (L)=7.8
ka (1/h)=0.0143
IIV-CL/F: 32.6%
IIV-V/F: 35.6%
IIV-ka: 103.9%
Prop = −16.6%
M6 Sánchez-Hernández et al., 2020 104 adult IBD patients (303) CL/F (L/h)=0.0157· (BMI/23.7)1.11· (1+1.20· UDASC)· (1+0.24· PEN)· (FCP/74)0.064
V/F (L)=11.2
ka (1/h)=0.00625 FIX
IIV-CL/F: 23.2% Prop = 21.7%

IIV: inter-individual variability; CV: coefficient of variation; CD: Crohn’s disease; IBD: Inflammatory Bowel Disease; WT: weight; AAA: antibodies against adalimumab; DOSING: adalimumab dosing regimen (0: every other week, 1: every week); UDASC: unexplained decline in adalimumab serum concentrations (0: NO, 1: YES); PEN: administration pen device during maintenance phase (0:40 mg, 1:80 mg); FCP: fecal calprotectin; add:additive error; prop: proportional error; NA: not available. The M numbers represent the selected models.